Adaptimmune Therapeutics PLC
(NAS:ADAP)
$
0.6229
-0.0032 (-0.51%)
Market Cap: 160.21 Mil
Enterprise Value: 56.80 Mil
PE Ratio: 0
PB Ratio: 2.12
GF Score: 64/100 Adaptimmune Therapeutics PLC at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020 / 12:00PM GMT
Release Date Price:
$8
(+1.39%)
Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst
Great. Thank you, everyone, for joining us today. My name is Mohit Bansal, and I'm one of the biotech analysts here at Citi, and I welcome you all for Citi's 15th Annual Biopharma Virtual Conference. And to kick off my sessions in this conference, we have -- we are pleased to have Adaptimmune management team joining us today. We are joined by Gavin Wood, the CFO; John Lunger, the Chief Patient Supply Officer; Mark Dudley, the SVP of Early stage Development, and also Elliot Norry, MD and Chief Medical Officer of the company. Thank you, all of you for joining us today.
Gavin Hilary James Wood
Adaptimmune Therapeutics plc - CFO
Thank you.
Elliot Norry
Adaptimmune Therapeutics plc - Senior VP & Chief Medical Officer
Thank you.
Questions & Answers
Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst
Great. So Elliot, this has been a quite eventful year for Adaptimmune. You
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot